Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden

Ozols, 2006, Challenges for chemotherapy in ovarian cancer, Ann Oncol, 17, v181, 10.1093/annonc/mdj978

Gabra, 2010, Back to the future: targeting molecular changes for platinum resistance reversal, Gynecol Oncol, 118, 210, 10.1016/j.ygyno.2010.06.028

Kipps, 2013, Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research, Nat Rev Cancer, 13, 273, 10.1038/nrc3432

Jekunen, 1994, Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro, Br J Cancer, 69, 299, 10.1038/bjc.1994.55

Aguilar-Gallardo, 2012, Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches, Stem Cell Rev, 8, 994, 10.1007/s12015-011-9344-5

Ahmed, 2013, Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance, J Cell Biochem, 114, 21, 10.1002/jcb.24317

Ahmed, 2013, Ovarian cancer stem cells: molecular concepts and relevance as therapeutic targets, Mol Aspects Med, 10.1016/j.mam.2013.06.002

Alvero, 2009, Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance, Cell Cycle, 8, 158, 10.4161/cc.8.1.7533

Latifi, 2012, Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors, PLoS One, 7, e46858, 10.1371/journal.pone.0046858

Steg, 2012, Stem cell pathways contribute to clinical chemoresistance in ovarian cancer, Clin Cancer Res, 18, 869, 10.1158/1078-0432.CCR-11-2188

Arwert, 2012, Epithelial stem cells, wound healing and cancer, Nat Rev Cancer, 12, 170, 10.1038/nrc3217

Gatcliffe, 2008, Wnt signaling in ovarian tumorigenesis, Int J Gynecol Cancer, 18, 954, 10.1111/j.1525-1438.2007.01127.x

Kwon, 2011, Notch post-translationally regulates beta-catenin protein in stem and progenitor cells, Nat Cell Biol, 13, 1244, 10.1038/ncb2313

Shodeinde, 2012, Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects, Onco Targets Ther, 5, 119, 10.2147/OTT.S32559

Colomiere, 2009, Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas, Br J Cancer, 100, 134, 10.1038/sj.bjc.6604794

Ernst, 2011, Stat3: linking inflammation to (gastrointestinal) tumourigenesis, Clin Exp Pharmacol Physiol, 39, 711, 10.1111/j.1440-1681.2011.05659.x

Sansone, 2012, Targeting the interleukin-6/Jak/stat pathway in human malignancies, J Clin Oncol, 30, 1005, 10.1200/JCO.2010.31.8907

Wang, 2012, STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review), Int J Oncol, 41, 1181, 10.3892/ijo.2012.1568

Groner, 2008, The function of Stat3 in tumor cells and their microenvironment, Semin Cell Dev Biol, 19, 341, 10.1016/j.semcdb.2008.06.005

Song, 2003, Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells, Oncogene, 22, 4150, 10.1038/sj.onc.1206479

Kim, 2007, Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis, Mol Carcinog, 46, 725, 10.1002/mc.20342

Grandis, 2000, Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo, Proc Natl Acad Sci U S A, 97, 4227, 10.1073/pnas.97.8.4227

Sherry, 2009, STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells, Stem Cells, 27, 2383, 10.1002/stem.185

Matthews, 2011, Absolute requirement for STAT3 function in small-intestine crypt stem cell survival, Cell Death Differ, 18, 1934, 10.1038/cdd.2011.77

Bourguignon, 2008, Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells, J Biol Chem, 283, 17635, 10.1074/jbc.M800109200

Ahmed, 2010, Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer, Curr Cancer Drug Targets, 10, 268, 10.2174/156800910791190175

Duan, 2006, Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer, Clin Cancer Res, 12, 5055, 10.1158/1078-0432.CCR-06-0861

Costantino, 2008, STAT 3 as a target for cancer drug discovery, Curr Med Chem, 15, 834, 10.2174/092986708783955464

Abubaker, 2013, Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden, Mol Cancer, 12, 24, 10.1186/1476-4598-12-24

Buick, 1985, Comparative properties of five human ovarian adenocarcinoma cell lines, Cancer Res, 45, 3668

Shield, 2007, Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis, J Carcinog, 6, 11, 10.1186/1477-3163-6-11

Yao, 2006, Sexually dimorphic regulation of inhibin beta B in establishing gonadal vasculature in mice, Biol Reprod, 74, 978, 10.1095/biolreprod.105.050286

Luwor, 2013, Targeting Stat3 and Smad7 to restore TGF-beta cytostatic regulation of tumor cells in vitro and in vivo, Oncogene, 32, 2433, 10.1038/onc.2012.260

Mofid, 2007, Relation between HER-2 gene expression and Gleason score in patients with prostate cancer, Urol J, 4, 101

Jennet, 1999, Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer, J Clin Oncol, 17, 1474, 10.1200/JCO.1999.17.5.1474

Monaghan, 2011, The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells, Leukemia, 25, 1891, 10.1038/leu.2011.175

Tyner, 2010, CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms, Blood, 115, 5232, 10.1182/blood-2009-05-223727

Creighton, 2009, Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features, Proc Natl Acad Sci U S A, 106, 13820, 10.1073/pnas.0905718106

Todaro, 2007, Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4, Cell Stem Cell, 1, 389, 10.1016/j.stem.2007.08.001

Shaked, 2008, Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents, Cancer Cell, 14, 263, 10.1016/j.ccr.2008.08.001

Mackie, 2011, CD34-positive stem cells: in the treatment of heart and vascular disease in human beings, Tex Heart Inst J, 38, 474

Kawamoto, 2007, Role of progenitor endothelial cells in cardiovascular disease and upcoming therapies, Catheter Cardiovasc Interv, 70, 477, 10.1002/ccd.21292

Kumar, 2014, Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer, Br J Cancer, 110, 133, 10.1038/bjc.2013.673

Kulbe, 2012, A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment, Cancer Res, 72, 66, 10.1158/0008-5472.CAN-11-2178

Kryczek, 2000, IL-6 production in ovarian carcinoma is associated with histotype and biological characteristics of the tumour and influences local immunity, Br J Cancer, 82, 621, 10.1054/bjoc.1999.0973

Wang, 2010, Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells, Cancer Lett, 295, 110, 10.1016/j.canlet.2010.02.019